Skip Navigation

Annals of Oncology 2005 16(Supplement 4):iv14-iv19; doi:10.1093/annonc/mdi902
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (20)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Paradiso, A.
Right arrow Articles by Lorusso, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paradiso, A.
Right arrow Articles by Lorusso, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Invited Paper

Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer

A. Paradiso1,*, A. Mangia1, A. Chiriatti1, S. Tommasi1, A. Zito2, A. Latorre3, F. Schittulli4 and V. Lorusso3

1 Clinical Experimental Oncology Laboratory, 2 Histopathology Service, 3 Medical Oncology Unit, 4 Women's Department, National Cancer Institute, via Amendola 209, 70125 Bari, Italy

* Correspondence to: Dr Angelo Paradiso, Clinical Experimental Oncology Laboratory, National Cancer Institute, Via Amendola 209, 70126 Bari, Italy. Phone/Fax +39-080-5555561; Email: a.paradiso{at}oncologico.bari.it

Background: Several studies looked for tumor biomarkers predictive for paclitaxel sensitivity but till now no reliable biomarkers are available. The aim of this study was to verify the potential predictive value of ß-tubulin III and IV, vascular endothelial growth factor-receptor (VEGFR-1), HER2/neu and microvessel density (mVD), in a group of 70 patients with advanced breast cancer (ABC) treated with paclitaxel-based chemotherapy.

Patients and methods: Immunohistochemical analysis (ICA) of HER2, VEGFR-1, mVd, ß-tubulin III and ß-tubulin IV expression were performed in a series of 72 advanced breast cancer. Furthermore apoptotic fraction with TUNEL analysis was evaluated.

Results: ß–tubulin III ICA expression was predictive of progression after chemotherapy. In fact only 2% of the patients with low ß-tubulin III expression progressed after paclitaxel chemotherapy vs 38% of those with high ß-tubulin III tumor expression (P=0.000; by {chi}2). This evidence was confirmed by a logistic regression analysis (OR 28.789; 95% CI 3.212–258,072; P=0.004). There was not a significant association between other biomarkers' characteristics and clinical response to chemotherapy. A Cox multivariate analysis, with overall survival as a dependent variable, showed that only HER2 expression was independently associated (OR 2.39; 95% CI 1.09–5.23; P=0.03) with overall survival.

Conclusions: We suggest that class III ß-tubulin immunohistochemical expression analysis could be a potentially relevant tumor biomarker for paclitaxel resistance in advanced breast cancer patients.

Key words: breast cancer, taxane, predictive factor, tubulin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
C. M. Galmarini, I. Treilleux, F. Cardoso, C. Bernard-Marty, V. Durbecq, D. Gancberg, M.-C. Bissery, M. Paesmans, D. Larsimont, M. J. Piccart, et al.
Class III {beta}-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel
Clin. Cancer Res., July 15, 2008; 14(14): 4511 - 4516.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. Cicchillitti, R. Penci, M. Di Michele, F. Filippetti, D. Rotilio, M. B. Donati, G. Scambia, and C. Ferlini
Proteomic characterization of cytoskeletal and mitochondrial class III {beta}-tubulin
Mol. Cancer Ther., July 1, 2008; 7(7): 2070 - 2079.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Prislei, S. Mozzetti, F. Filippetti, M. De Donato, G. Raspaglio, L. Cicchillitti, G. Scambia, and C. Ferlini
From plasma membrane to cytoskeleton: a novel function for semaphorin 6A
Mol. Cancer Ther., January 1, 2008; 7(1): 233 - 241.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Seve, R. Lai, K. Ding, T. Winton, C. Butts, J. Mackey, C. Dumontet, L. Dabbagh, S. Aviel-Ronen, L. Seymour, et al.
Class III {beta}-Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non-Small Cell Lung Cancer: Analysis of NCIC JBR.10
Clin. Cancer Res., February 1, 2007; 13(3): 994 - 999.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Ferrandina, G. F. Zannoni, E. Martinelli, A. Paglia, V. Gallotta, S. Mozzetti, G. Scambia, and C. Ferlini
Class III {beta}-Tubulin Overexpression Is a Marker of Poor Clinical Outcome in Advanced Ovarian Cancer Patients.
Clin. Cancer Res., May 1, 2006; 12(9): 2774 - 2779.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. Seve, J. Mackey, S. Isaac, O. Tredan, P.-J. Souquet, M. Perol, R. Lai, A. Voloch, and C. Dumontet
Class III {beta}-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel
Mol. Cancer Ther., December 1, 2005; 4(12): 2001 - 2007.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.